Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- MHLW Eyes Budget Request to Set Up Cost-Effective Analysis Regime, Report Due Out Summer
May 28, 2015
- MHLW Approves MSD’s Pegintron for Adjuvant Therapy for Malignant Melanoma
May 27, 2015
- MHLW to Set Generic Share Target of 80% by FY2020-End: Shiozaki
May 27, 2015
- MHLW Notifies of Package Insert Change for Plavix
May 27, 2015
- ICH Likely to OK Brazil, China as Assembly Members at Fukuoka Confab
May 26, 2015
- MHLW Grants Orphan Designation for Rituximab, Metirosine
May 26, 2015
- PAFSC 1st Committee to Review Lilly’s GLP-1 Receptor Agonist Dulaglutide on June 5
May 25, 2015
- Editor’s Pick: Five Healthcare News Headlines for May 11 - May 24
May 25, 2015
- Considerable Resolve Needed for Proposed 80% Generic Target: JGA
May 25, 2015
- JSGM President Muto Calls for “Favorable Environment” to Promote Use of Biosimilars
May 25, 2015
- Govt Panel Members Renew Call for Annual Drug Price Cuts, Amari Says Conclusion Out after 2016-2018 Consecutive Revisions
May 20, 2015
- Panel OKs Sovaldi for Medical Subsidy, Monthly Copay at 10,000-20,000 Yen
May 19, 2015
- Generic Drug Use May Reach 60% Target Ahead of Schedule, but Raising Target to 80% Would Be “Difficult”: Director Jo of EAD
May 18, 2015
- PAFSC Second Committee to Review Safety Information of Takeda’s Hib Vaccine on May 28
May 18, 2015
- MHLW Announces 196 Newly Designated Intractable Diseases
May 15, 2015
- PAFSC Second Committee to Discuss Gilead’s Combination Hepatitis C Treatment on May 28
May 15, 2015
- Chuikyo Reps Discuss HTA, Re-Pricing as Sovaldi Lands in Japan
May 14, 2015
- Chuikyo Approves Listing of 5 Drugs with Expected Peak Sales of Over 10 Billion Yen
May 14, 2015
- Sovaldi’s 5 Million Yen Price Tag OK’d for 12-Week Regimen, Listing on May 20
May 13, 2015
- MHLW Mulls Legal Disclosure of Drug Makers’ Clinical Research Payments
May 13, 2015
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…